| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.09.17 | Knight Transportation, Inc. and Swift Transportation Company Merge to Create North America's Premier Truckload Transportation Company | 167 | Business Wire | PHOENIX--(BUSINESS WIRE)--Knight-Swift Transportation Holdings Inc. ("Knight-Swift" or the "Company") (NYSE: "KNX") announced today the completion of the merger of Knight Transportation, Inc. and Swift... ► Artikel lesen | |
| 10.09.17 | Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma in Phase 3 CheckMate -214 Trial | 149 | Business Wire | Opdivo (nivolumab) plus Yervoy (ipilimumab) reduced the risk of death by 37% versus standard of care, sunitinib, in intermediate- and poor-risk patients The combination also significantly... ► Artikel lesen | |
| 10.09.17 | Daten aus der ECHO-202-Studie zum progressionsfreien Überleben mit Epacadostat in Kombination mit KEYTRUDA (Pembrolizumab) von Incyte bestätigen die Dauer des Ansprechens bei Patienten mit fortgeschrittenem Melanom | 367 | Business Wire | Aktuelle Daten werden auf dem Kongress der europäischen Gesellschaft für medizinische Onkologie 2017 vorgestellt Die Incyte Corporation (Nasdaq: INCY) gab heute aktuelle Daten aus der... ► Artikel lesen | |
| 10.09.17 | Top 5 Vendors in the Compensation Software Market From 2017 to 2021: Technavio | 85 | Business Wire | Technavio has announced the top five leading vendors in their recentglobal compensation software marketreport. This research report also lists 22 other prominent vendors that are expected... ► Artikel lesen | |
| 10.09.17 | Ipsen and Exelixis Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 | 211 | Business Wire | Independent Radiology Review Committee confirms primary endpoint analysis per investigator: cabozantinib provided statistically significant improvement of progression-free survival... ► Artikel lesen | |
| 10.09.17 | Exelixis and Ipsen Announce Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma at ESMO 2017 | 213 | Business Wire | - Independent Radiology Review Committee confirms primary endpoint analysis per investigator: cabozantinib provided statistically significant improvement of progression-free survival, with... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 2.544 |
| VARTA | 2.469 |
| RHEINMETALL | 2.388 |
| NEL | 2.103 |
| RENK GROUP | 1.606 |
| NVIDIA | 1.553 |
| DEUTSCHE LUFTHANSA | 1.549 |
| TESLA | 1.535 |
| BAYER | 1.270 |
| AIXTRON SE | 1.178 |
| BYD | 1.031 |
| DEUTSCHE BANK | 805 |
| SARTORIUS AG VZ | 798 |
| BASF | 756 |
| NETFLIX | 736 |
| EVOTEC | 729 |
| RWE | 717 |
| ALLIANZ | 611 |
| COMMERZBANK | 609 |
| MERCEDES-BENZ | 605 |
| BARRICK GOLD | 602 |
| INFINEON | 595 |
| HENSOLDT | 590 |
| SUPER MICRO COMPUTER | 581 |
| VOLKSWAGEN | 547 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
